Loss of WISP-2/CCN5 signaling in human pancreatic cancer: A potential mechanism for epithelial-mesenchymal-transition

Cancer Letters

Volumn 254, Issue 1, 2007, Pages 63-70

  Dhar, Gopal ^a,b   Mehta, Smita ^a,b   Banerjee, Snigdha ^a,b   Gardner, Ashleigh ^a   McCarty, Bryan M ^a   Mathur, Sharad C ^a,b   Campbell, Donald R ^d   Kambhampati, Suman ^a,b   Banerjee, Sushanta K ^a,b,c  

^a VA Medical Center   (United States)

^b Department of Hematology and Oncology ^*  (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

p53 tumor suppressor gene; Pancreatic adenocarcinoma; WISP 2 CCN5

Indexed keywords

MESSENGER RNA; PROTEIN CCN5; PROTEIN P53; PROTEIN WISP 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CHRONIC PANCREATITIS; CONTROLLED STUDY; EPITHELIUM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MESENCHYME CELL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESODERM; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447297824     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.02.012     Document Type: Article

References (39)

1. Ko A.H., and Tempero M.A. Treatment of metastatic pancreatic cancer. J. Natl. Compr. Canc. Netw. 3 (2005) 627-636
2. Brand R., and Mahr C. Risk factors for pancreatic adenocarcinoma: are we ready for screening and surveillance?. Curr. Gastroenterol. Rep. 7 (2005) 122-127
3. Rodriguez J.A., Li M., Yao Q., Chen C., and Fisher W.E. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J. Surg. 29 (2005) 297-305
4. Maitra A., Adsay N.V., Argani P., Iacobuzio-Donahue C., De M.A., Cameron J.L., Yeo C.J., and Hruban R.H. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. 16 (2003) 902-912
5. Abraham S.C., Wilentz R.E., Yeo C.J., Sohn T.A., Cameron J.L., Boitnott J.K., and Hruban R.H. Pancreatico duodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'?. Am. J. Surg. Pathol. 27 (2003) 110-120
6. Aguirre A.J., Brennan C., Bailey G., Sinha R., Feng B., Leo C., Zhang Y., Zhang J., Gans J.D., Bardeesy N., Cauwels C., Cordon-Cardo C., Redston M.S., DePinho R.A., and Chin L. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc. Natl. Acad. Sci. USA 101 (2004) 9067-9072
7. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., and DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17 (2003) 3112-3126
8. Banerjee S.K., Zoubine M.N., Mullick M., Weston A.P., Cherian R., and Campbell D.R. Tumor angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: impact of K-ras mutations. Pancreas 20 (2000) 248-255
9. Brigstock D.R., Goldschmeding R., Katsube K.I., Lam S.C., Lau L.F., Lyons K., Naus C., Perbal B., Riser B., Takigawa M., and Yeger H. Proposal for a unified CCN nomenclature. Mol. Pathol. 56 (2003) 127-128
10. Pennica D., Swanson T.A., Welsh J.W., Roy M.A., Lawrence D.A., Lee J., Brush J., Taneyhill L.A., Deuel B., Lew M., Watanabe C., Cohen R.L., Melhem M.F., Finley G.G., Quirke P., Goddard A.D., Hillan K.J., Gurney A.L., Botstein D., and Levine A.J. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. USA 95 (1998) 14717-14722
11. Saxena N., Banerjee S., Sengupta K., Zoubine M.N., and Banerjee S.K. Differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines. Mol. Cell Biochem. 228 (2001) 99-104
12. Banerjee S., Saxena N., Sengupta K., Tawfik O., Mayo M.S., and Banerjee S.K. WISP-2 Gene in Human Breast Cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5 (2003) 63-73
13. Banerjee S., Sengupta K., Saxena N.K., Dhar K., and Banerjee S.K. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-{alpha}-positive breast tumor cells through multiple molecular cross-talks. Mol. Cancer Res. 3 (2005) 151-162
14. Ray G., Banerjee S., Saxena N.K., Campbell D.R., Van V.P., and Banerjee S.K. Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis. Oncol. Rep. 13 (2005) 445-448
15. Sengupta K., Banerjee S., Dhar K., Saxena N., Mehta S., Campbell D.R., and Banerjee S.K. WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Cα-mediated breast tumor cell proliferation. Biochemistry 45 (2006) 10698-10709
16. Zoubine M.N., Banerjee S., Saxena N.K., Campbell D.R., and Banerjee S.K. WISP-2: a serum-inducible gene differentially expressed in human normal breast epithelial cells and in MCF-7 breast tumor cells. Biochem. Biophys. Res. Commun. 282 (2001) 421-425
17. Mason H.R., Lake A.C., Wubben J.E., Nowak R.A., and Castellot Jr. J.J. The growth arrest-specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol. Hum. Reprod. 10 (2004) 181-187
18. Mitchell M.L., and Carney C.N. Cytologic criteria for the diagnosis of pancreatic carcinoma. Am. J. Clin. Pathol. 83 (1985) 171-176
19. Lankisch P.G., and Bank P.A. Pancreatitis (1997), Springer Verlag, Heidelberg, New York, Berlin
20. Rall C.J., Yan Y.X., Graeme-Cook F., Beauchamp R., Yandell D.W., Povoski S.P., and Rustgi A.K. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 12 (1996) 10-17
21. Dong M., Nio Y., Tamura K., Song M.M., Guo K.J., Guo R.X., and Dong Y.T. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 279-284
22. Ruggeri B., Zhang S.Y., Caamano J., DiRado M., Flynn S.D., and Klein-Szanto A.J. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7 (1992) 1503-1511
23. Yokoyama M., Yamanaka Y., Friess H., Buchler M., and Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. 14 (1994) 2477-2483
24. Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., and Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer 58 (1994) 185-191
25. Grutzmann R., Foerder M., Alldinger I., Staub E., Brummendorf T., Ropcke S., Li X., Kristiansen G., Jesnowski R., Sipos B., Lohr M., Luttges J., Ockert D., Kloppel G., Saeger H.D., and Pilarsky C. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch. 443 (2003) 508-517
26. Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., and Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 442 (2003) 444-452
27. Ikai K., and McGuire J.S. Phosphorylation of keratin polypeptides. Biochim. Biophys. Acta 760 (1983) 371-376
28. Omary M.B., Ku N.O., Liao J., and Price D. Keratin modifications and solubility properties in epithelial cells and in vitro. Subcell. Biochem. 31 (1998) 105-140
29. Paramio J.M. A role for phosphorylation in the dynamics of keratin intermediate filaments. Eur. J. Cell Biol. 78 (1999) 33-43
30. Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol. 178 (2003) 169-175
31. Bargonetti J., and Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14 (2002) 86-91
32. Barnes D.M., Hanby A.M., Gillett C.E., Mohammed S., Hodgson S., Bobrow L.G., Leigh I.M., Purkis T., MacGeoch C., and Spurr N.K. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340 (1992) 259-263
33. Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C., Neoptolemos J., and Williamson R.C. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 64 (1991) 1076-1082
34. Casey G., Yamanaka Y., Friess H., Kobrin M.S., Lopez M.E., Buchler M., Beger H.G., and Korc M. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 69 (1993) 151-160
35. Cowgill S.M., and Muscarella P. The genetics of pancreatic cancer. Am. J. Surg. 186 (2003) 279-286
36. Levine A.J., Chang A., Dittmer D., Notterman D.A., Silver A., Thorn K., Welsh D., and Wu M. The p53 tumor suppressor gene. J. Lab Clin. Med. 123 (1994) 817-823
37. Hoh J., Jin S., Parrado T., Edington J., Levine A.J., and Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA 99 (2002) 8467-8472
38. Radisky D.C. Epithelial-mesenchymal transition. J. Cell Sci. 118 (2005) 4325-4326
39. Thiery J.P., and Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7 (2006) 131-142